# How retatrutide targets three receptors Canonical: https://europeanpeptideshop.com/blog/retatrutide-mechanism-of-action/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Compound research · 8 November 2026 · 4 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page ## The proposed mechanism in outline Retatrutide (development code LY3437943) is a single peptide designed to activate three receptors at once: the receptor for glucose-dependent insulinotropic polypeptide (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). That is why it is called a triple agonist. Each receptor normally responds to a different natural hormone, and the design idea is one molecule that engages all three. Its development status and what the published trials report are covered on the [retatrutide identity page](https://europeanpeptideshop.com/blog/retatrutide/). This page is only about how the molecule is proposed to work. ## Molecular targets All three targets belong to the same receptor family. They are class B G protein-coupled receptors on the cell surface, and each signals mainly by raising intracellular cyclic AMP when activated. Receptor | Natural ligand | Where it is mainly found GLP-1R | GLP-1 | Pancreatic islet cells and parts of the brain GIPR | GIP | Pancreatic islet cells, adipose tissue and parts of the brain GCGR | Glucagon | Liver cells (hepatocytes) ### Model systems the targets were identified in The activity of the molecule at each receptor was characterised in cell-based assays, where cells engineered to carry one receptor are exposed to the peptide and the cyclic AMP response is measured. A 2022 paper by Coskun and colleagues in Cell Metabolism, written by the developer, reported that in vitro retatrutide showed balanced activity at GCGR and GLP-1R and greater activity at GIPR. Because the authors are the developer, this is developer-reported data and should be read as such. ## Demonstrated versus inferred The evidence tier matters more here than the headline. A claim about a receptor in a dish is a different kind of claim from a claim about a person. Statement | Evidence tier | Status The peptide activates GIPR, GLP-1R and GCGR | In vitro | Demonstrated in cell assays, developer-reported Activity is balanced at GCGR and GLP-1R, higher at GIPR | In vitro | Demonstrated in cell assays, developer-reported Adding glucagon-receptor activity raises energy expenditure in obese mice | Animal | Reported in mice only Each receptor's separate contribution in humans | Human | Inferred, not isolated The last row is a limit of the design rather than a gap in effort. When one molecule acts on three receptors together, the contribution of each cannot be separated by studying that molecule alone. Statements about what each receptor adds in people are inferences from related single and dual agonists. ## How this differs from adjacent compounds The contrast is in receptor coverage, not in a product comparison. Compound | Receptors engaged Semaglutide | GLP-1R Tirzepatide | GIPR and GLP-1R Retatrutide | GIPR, GLP-1R and GCGR Semaglutide and tirzepatide are the names of licensed medicines. This page compares receptor pharmacology only and says nothing about their clinical use. The three compounds are set side by side in the [retatrutide, tirzepatide and semaglutide research comparison](https://europeanpeptideshop.com/blog/retatrutide-vs-tirzepatide-vs-semaglutide/). The glucagon receptor is the distinguishing element. Glucagon is traditionally associated with raising blood glucose, so how the glucagon component is balanced against the other two receptors is a design question, and the mouse data above is the main published basis for including it. ## Open questions - Human contribution of each receptor. Not separable from a single triple agonist, as above. - Independent data. Most of the mechanistic characterisation is reported by the developer. Independent replication in the open literature is thinner. - The research reagent versus the clinical product. Published mechanism describes the developer's molecule. Whether a given research batch matches it is a question of identity and purity, which is what a batch certificate in the [COA publication status](https://europeanpeptideshop.com/coa/) addresses. A certificate reports what was measured in that batch and nothing about biological activity. The catalogue items are the [retatrutide 10mg](https://europeanpeptideshop.com/shop/retatrutide-10mg/), [20mg](https://europeanpeptideshop.com/shop/retatrutide-20mg/) and [30mg](https://europeanpeptideshop.com/shop/retatrutide-30mg/) vials, and the [retatrutide vial guide](https://europeanpeptideshop.com/blog/retatrutide-vial/) explains how to check a vial against its paperwork. ## EPS documentation Use the [research catalogue](https://europeanpeptideshop.com/shop/) to check the exact name, labelled amount and format. The [COA library](https://europeanpeptideshop.com/coa/) publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526.](https://doi.org/10.1056/NEJMoa2301972) - [Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472.](https://doi.org/10.1016/S0140-6736%2826%2901861-1) ## Related listings [10 mg](https://europeanpeptideshop.com/shop/retatrutide-10mg/) Metabolic research ### [Retatrutide](https://europeanpeptideshop.com/shop/retatrutide-10mg/) 10 mg · Lyophilised powder Ordering opens later. Prices and availability are not yet published.[Details](https://europeanpeptideshop.com/shop/retatrutide-10mg/) ## More articles Compound research · 6 min read ## [Retatrutide research evidence](https://europeanpeptideshop.com/blog/retatrutide-research-evidence/) Retatrutide evidence by study type, including the October 2026 Ozempic comparator announcement, registry details and limits of sponsor-reported trial. 8 November 2026 Compound research · 3 min read ## [Retatrutide side effects in trials](https://europeanpeptideshop.com/blog/retatrutide-side-effects/) Which adverse events were reported in published retatrutide trials, how often, and what those trials can and cannot tell you. 8 November 2026 Compound research · 2 min read ## [Understanding retatrutide vial labels](https://europeanpeptideshop.com/blog/retatrutide-vial/) What a retatrutide research vial contains, what 10mg looks like, and how to check a vial against its batch certificate. 8 November 2026